Oncology

Cervical Cancer Drugs: Industry Trends and Opportunity Forecast, 2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 15, 2022 - 4:02pm

The "Cervical Cancer Drugs Global Market Report 2022, Cancer Type, Drug Type, Distribution Channel" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Cancer Drugs Global Market Report 2022, Cancer Type, Drug Type, Distribution Channel" report has been added to ResearchAndMarkets.com's offering.
  • North America is the largest region in the cervical cancer drugs market in 2021.
  • The increasing prevalence of HIV (Human immunodeficiency virus) in women is driving the growth of the cervical cancer drugs market.
  • The lack of awareness and other misconceptions about cervical cancers hinder the growth of the cervical cancer drugs market.

Pioneering Engineer-Researcher to Receive 2022 Szent-Györgyi Prize for Progress in Cancer Research

Retrieved on: 
Monday, August 15, 2022 - 2:00pm

The National Foundation for Cancer Research (NFCR) announced today that Rakesh K. Jain, Ph.D., has been selected to receive the 2022 Szent-Gyrgyi Prize for Progress in Cancer Research.

Key Points: 
  • The National Foundation for Cancer Research (NFCR) announced today that Rakesh K. Jain, Ph.D., has been selected to receive the 2022 Szent-Gyrgyi Prize for Progress in Cancer Research.
  • Dr. Rakesh Jains seminal discoveries in basic and translational research have guided numerous fields in cancer research with the promise of saving lives.
  • These are the pillars of the Szent-Gyrgyi Prize, said Sujuan Ba, Ph.D., co-chair of the 2022 Prize selection committee and President and CEO of NFCR.
  • The Szent-Gyrgyi Prize for Progress in Cancer Research was established by the National Foundation for Cancer Research in honor of its co-founder, Albert Szent-Gyrgyi, M.D., Ph.D., recipient of the 1937 Nobel Prize for Physiology and Medicine.

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

Retrieved on: 
Monday, August 15, 2022 - 1:30pm

Pursuant to the Agreement, Iroquois director designees, Jonathan L. Schechter and Joshua N. Silverman, will join PharmaCytes reconstituted Board as independent directors.

Key Points: 
  • Pursuant to the Agreement, Iroquois director designees, Jonathan L. Schechter and Joshua N. Silverman, will join PharmaCytes reconstituted Board as independent directors.
  • Our reconstituted Board combines extensive science, operating and capital markets experience that will make PharmaCyte a much stronger company.
  • Each resigned from the Board as part of the Cooperation Agreement after determining that the Cooperation Agreement, including the composition of the new Board, was in the best interest of the Company moving forward.
  • Richard Abbe, President of Iroquois, concluded, We appreciate the engagement we have had with PharmaCyte and its shareholders over the last several months.

RenovoRx Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 15, 2022 - 1:00pm

RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform, today reported its financial results for the quarter ended June 30, 2022.

Key Points: 
  • RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform, today reported its financial results for the quarter ended June 30, 2022.
  • Financial Highlights for the Quarter Ended June 30, 2022
    As of June 30, 2022, the Company had cash and cash equivalents and short-term marketable securities of $10.8 million.
  • Research and development expenses were $1.4 million for the quarter ended June 30, 2022, compared to $0.5 million for the quarter ended June 30, 2021.
  • General and administrative expenses were $1.2 million for the quarter ended June 30, 2022, compared to $0.3 million for the quarter ended June 30, 2021.

Guardant Health Expands Use of Guardant Reveal™ Liquid Biopsy Test for Residual Disease Detection and Recurrence Monitoring to Include Early-Stage Breast and Lung Cancers

Retrieved on: 
Monday, August 15, 2022 - 1:05pm

The Guardant Reveal test may be initiated as soon as three weeks after surgery.

Key Points: 
  • The Guardant Reveal test may be initiated as soon as three weeks after surgery.
  • Guardant Reveal is the first blood-only test that detects residual and recurrent disease in patients with Stage II and III CRC, breast or lung cancer without the need for a tissue biopsy.
  • Guardant Health has commercially launched Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal for early-stage cancer patients.
  • The Guardant Health screening portfolio, including the Shield test, aims to address the needs of individuals eligible for cancer screening.

HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200301 in Combination with Tislelizumab in Patients with DIS™ Selected Advanced Solid Tumors

Retrieved on: 
Monday, August 15, 2022 - 1:03pm

Combination immunotherapy approaches have become a promising solution for harder to treat cancers, said Luigi Manenti, M.D., Chief Medical Officer at HiFiBiO Therapeutics.

Key Points: 
  • Combination immunotherapy approaches have become a promising solution for harder to treat cancers, said Luigi Manenti, M.D., Chief Medical Officer at HiFiBiO Therapeutics.
  • We are excited to explore whether HFB200301 in combination with tislelizumab can further improve patient outcomes in DIS selected cancers.
  • HiFiBiO is proud to highlight the potential of our DIS platform to rapidly advance novel therapeutics like HFB200301 from targets to patients.
  • www.hifibio.com
    HiFiBiO Therapeutics, HiFiBiO Therapeutics logo, and DIS are trademarks of HiFiBiO and its affiliates.

EpiAxis Therapeutics & Peptilogics Enter Strategic Drug Discovery Partnership

Retrieved on: 
Monday, August 15, 2022 - 1:30pm

The collaboration will combine EpiAxis Therapeutics deep epigenetic expertise and Peptilogics AI platform (Nautilus) to advance drug discovery for cancers that escape existing therapies through epigenetic change, including metastatic breast cancer.

Key Points: 
  • The collaboration will combine EpiAxis Therapeutics deep epigenetic expertise and Peptilogics AI platform (Nautilus) to advance drug discovery for cancers that escape existing therapies through epigenetic change, including metastatic breast cancer.
  • Peptilogics Nautilus platform enables in silico predictive peptide design across diverse targets to efficiently access new functional chemical space and design therapeutics.
  • We are equally delighted to launch this collaboration with EpiAxis Therapeutics, a pioneer in the field of epigenetic cancer therapy, said Nicholas Nystrom PhD, Chief Technology Officer of Peptilogics.
  • This strategic partnership follows the recent publication of the results of EpiAxis' pioneering clinical trial EPI-PRIMED in leading cancer journal Frontiers in Oncology.

CEL-SCI Corporation Reports Third Quarter Fiscal 2022 Financial Results

Retrieved on: 
Monday, August 15, 2022 - 2:00pm

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2022, as well as key clinical and corporate developments.

Key Points: 
  • CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2022, as well as key clinical and corporate developments.
  • This indicates that the likelihood of seeing these results by chance is less than 1 in ten billion.
  • These results confirm findings from the Phase 1 and 2 studies with Multikine and provide direct evidence of Multikines anticancer activity.
  • The study results announced showed almost 4-year survival benefit for those patients who received Multikine treatment regimen plus surgery and radiation.

TerraPower Announces $750 Million Secured in Fundraise

Retrieved on: 
Monday, August 15, 2022 - 1:52pm

TerraPower, a leading nuclear innovation company, announced today the close of an equity raise that yields a minimum of $750 million.

Key Points: 
  • TerraPower, a leading nuclear innovation company, announced today the close of an equity raise that yields a minimum of $750 million.
  • The fundraise was co-led by SK Inc. and SK Innovation (collectively, SK) and TerraPowers founder Bill Gates.
  • This fundraise enhances TerraPowers groundbreaking work in advanced nuclear energy technologies and nuclear medicine.
  • TerraPower is committed to solving some of the toughest challenges that face this generation through innovation, said TerraPower President and CEO Chris Levesque.

Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic Cancers

Retrieved on: 
Monday, August 15, 2022 - 1:55pm

Identification and tracking of MRD is an emerging focus in the clinical care of patients with gastrointestinal cancers such as colorectal and pancreatic cancer, which may improve overall clinical management throughout a patients journey.

Key Points: 
  • Identification and tracking of MRD is an emerging focus in the clinical care of patients with gastrointestinal cancers such as colorectal and pancreatic cancer, which may improve overall clinical management throughout a patients journey.
  • Approximately 220 patients will be recruited for this study from across British Columbia to assess how ctDNA can improve cancer care delivery.
  • Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics.
  • To enable cancer sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale and efficiency.